Sunshine Biopharma (SBFM) Revenue (2015 - 2026)

Sunshine Biopharma (SBFM) has reported Revenue for 10 consecutive years, with $9.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue fell 1.56% year-over-year to $9.3 million; the trailing twelve-month figure through Jun 2026 stood at $35.3 million (down 2.74% YoY), and the FY2025 full-year result was $36.3 million, up 4.11% from the prior year.
• Revenue climbed to $9.3 million in Q2 2026 per SBFM's latest filing, from $8.1 million in the prior quarter.
• Across five years, Revenue topped out at $9.6 million in Q4 2024 and bottomed at $122645.0 in Q1 2022.
• Historically, Revenue has averaged $6.5 million across 5 years, with a median of $7.9 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Revenue surged 4528.68% in 2022, then dropped 10.61% in 2025.
• Over 5 years, Revenue stood at $3.9 million in 2022, then surged by 94.94% to $7.7 million in 2023, then advanced by 24.93% to $9.6 million in 2024, then decreased by 10.61% to $8.6 million in 2025, then increased by 8.0% to $9.3 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $9.3 million, $8.1 million, and $8.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.